← ANALYST RATINGS · TIPRANKS
PROCEPT BioRobotics (PRCT): analyst forecast and price target
Analyst consensus
Hold4 Buy7 Hold1 Sell
Ratings of 12 analysts in the last 3 months12-month forecast
Based on 12 price targets given in the last 3 months, the average target is $22.89, the highest $30.00, the lowest $19.00. The average is +30.3% from the last price of $17.57.
Analyst ratings 14
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Adam Maeder★★★★★★★★★★#1026 · hits 54% · avg +11.3% | Piper Sandler | $25.00 | Buy | +42.3% | Reiterated | 16.10.26on TipRanks 08:08 | −2.1% | ↗ |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $21.00 → $20.50−2.4% | Hold | +16.7% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $19.50 → $19.00−2.6% | Hold | +8.1% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $20.00 → $19.50−2.5% | Hold | +11.0% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $19.50 → $19.00−2.6% | Hold | +8.1% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $20.50 → $20.00−2.4% | Hold | +13.8% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $19.50 → $19.00−2.6% | Hold | +8.1% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| Mike Kratky★★★★★★★★★★#1691 · hits 46% · avg +12.9% | Leerink Partners | $21.00 → $20.00−4.8% | Hold | +13.8% | Assigned | 12.10.26on TipRanks 07:35 | +6.4%next day −2.4% | ↗ |
| Christopher Pasquale★★★★★★★★★★#1776 · hits 61% · avg +11.9% | Nephron | $30.00 | Buy | +70.7% | Initiated | 06.10.26on TipRanks Oct 7 21:15 | −2.3%next day +2.5% · 5 days +9.2% | ↗ |
| Ryan Zimmerman★★★★★★★★★★#3375 · hits 46% · avg +3.3% | BTIG | — | Hold | — | Reiterated | 31.08.26on TipRanks Sep 1 06:30 | +2.1%next day −0.7% · 5 days +0.9% | ↗ |
| Brandon Vazquez★★★★★★★★★★#11688 · hits 42% · avg −5.1% | William Blair | — | Hold | — | Downgrade | 08.08.26on TipRanks Aug 9 09:20 | +6.4%next day +5.8% · 5 days −2.8% | ↗ |
| Stephanie Piazzola★★★★★★★★★★#10725 · hits 29% · avg −13.2% | Bank of America Securities | — | Sell | — | Reiterated | 05.08.26on TipRanks 13:25 | +6.0%next day +3.7% · 5 days +9.5% | ↗ |
| Vijay Kumar★★★★★★★★★★#2375 · hits 54% · avg +4.8% | Evercore ISI | $30.00 → $23.00−23.3% | Buy | +30.9% | Reiterated | 05.08.26on TipRanks 08:20 | +6.0%next day +3.7% · 5 days +9.5% | ↗ |
| Richard Newitter★★★★★★★★★★#1772 · hits 48% · avg +6.6% | Truist Financial | $25.00 → $21.00−16.0% | Hold | +19.5% | Reiterated | 05.08.26on TipRanks 07:55 | +6.0%next day +3.7% · 5 days +9.5% | ↗ |
| David Rescott★★★★★★★★★★#3448 · hits 49% · avg +5.1% | Robert W. Baird | $24.00 → $20.00−16.7% | Hold | +13.8% | Reiterated | 05.08.26on TipRanks 07:40 | +6.0%next day +3.7% · 5 days +9.5% | ↗ |
| Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% | UBS | $20.00 | Hold | +13.8% | Reiterated | 05.08.26on TipRanks 07:35 | +6.0%next day +3.7% · 5 days +9.5% | ↗ |
| Matthew O'Brien★★★★★★★★★★#12031 · hits 41% · avg −4.5% | Piper Sandler | $35.00 → $25.00−28.6% | Buy | +42.3% | Reiterated | 05.08.26on TipRanks 07:35 | +6.0%next day +3.7% · 5 days +9.5% | ↗ |
| Nathan Treybeck★★★★★★★★★★#10843 · hits 28% · avg −5.3% | Wells Fargo | $34.00 → $19.00−44.1% | Hold | +8.1% | Downgrade | 05.08.26on TipRanks 07:20 | +6.0%next day +3.7% · 5 days +9.5% | ↗ |
| Josh Jennings★★★★★★★★★★#3537 · hits 46% · avg +3.0% | TD Cowen | $34.00 → $28.00−17.6% | Buy | +59.4% | Assigned | 05.08.26on TipRanks 02:55 | +6.0%next day +3.7% · 5 days +9.5% | ↗ |
| Suraj Kalia★★★★★★★★★★#1646 · hits 50% · avg +6.8% | Oppenheimer | $60.00 | Hold | +241.5% | Downgrade | 26.02.26on TipRanks 07:25 | −14.6%next day −3.5% · 5 days +8.4% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering PROCEPT BioRobotics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $22.29 at a price of $18.22 (+22.3%); now: $22.89 at $17.57 (+30.3%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Buy | 13 | 11 | 7 | 7 | 3 | 4 |
| Hold | 4 | 5 | 6 | 14 | 12 | 9 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.39 (from $-0.43 to $-0.34). Last quarter: $-0.47.
Sales
Next quarter’s sales estimate — $101M (from $96M to $104M). Last quarter: $94M.
Best top-analyst consensus in the sector · Healthcare
About PROCEPT BioRobotics
- CEO: Larry L. Wood
- Employees: 888
- 150 Baytech Drive, San Jose, CA, 95134, US
- www.procept-biorobotics.com
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
Data from the stock’s TipRanks forecast page, read 48 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗